Top Page
Consun Pharmaceutical Group Ltd.
(Frankfurt:1681)
Consun Pharmaceutical Group Ltd. (1681) vs. S&P 500 (SPY)
Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model
Consun Pharmaceutical Group Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.59B | 2.34B | 2.04B | 1.75B | 1.73B | Gross Profit |
| 1.92B | 1.76B | 1.53B | 1.32B | 1.26B | EBIT |
| 884.97M | 715.41M | 660.18M | 550.13M | 496.38M | EBITDA |
| 963.06M | 785.89M | 728.71M | 618.79M | 566.36M | Net Income Common Stockholders |
| 784.53M | 682.91M | 590.17M | 498.79M | 79.82M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.58B | 3.04B | 2.43B | 1.94B | 1.38B | Total Assets |
| 5.51B | 4.89B | 4.36B | 3.95B | 3.71B | Total Debt |
| 511.53M | 460.18M | 610.97M | 549.41M | 553.57M | Net Debt |
| -2.24B | -1.99B | -1.59B | -1.39B | -829.66M | Total Liabilities |
| 1.59B | 1.45B | 1.45B | 1.43B | 1.40B | Stockholders Equity |
| 3.63B | 3.15B | 2.62B | 2.22B | 1.99B |
| Cash Flow | Free Cash Flow | |||
| 766.41M | 896.09M | 627.29M | 818.36M | 203.57M | Operating Cash Flow |
| 818.97M | 947.68M | 725.54M | 867.06M | 383.31M | Investing Cash Flow |
| -231.77M | -368.80M | -298.31M | -25.70M | -110.13M | Financing Cash Flow |
| -280.10M | -342.20M | -166.66M | -279.80M | -156.66M |
Consun Pharmaceutical Group Ltd. Technical Analysis
Consun Pharmaceutical Group Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | €8.01B | 8.02 | 23.28% | 7.63% | 12.70% | 9.91% | |
74 Outperform | $30.26B | 10.46 | 14.56% | 5.66% | -5.37% | 6.28% | |
66 Neutral | $71.04B | 37.42 | 6.14% | 1.49% | 7.63% | -24.23% | |
65 Neutral | HK$60.52B | 12.24 | 6.22% | 1.97% | -2.82% | 11.93% | |
62 Neutral | €30.78B | 8.47 | 5.71% | ― | ― | ||
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% |
Consun Pharmaceutical Group Ltd. Corporate Events
Consun Pharmaceutical Group Ltd. announced that its product, Kidney Repair and Edema Alleviation Granules, has been approved as a Class 2 Protected Product of Traditional Chinese Medicine by the National Medical Products Administration. This approval grants the product a state protection period of seven years, during which other enterprises are prohibited from imitating it. The recognition is expected to support the company’s long-term development and strengthen its market position.
Consun Pharmaceutical Group Ltd. has received approval from the National Medical Products Administration to commence clinical trials for its SK-09 Tablet, a Category 1 chemical drug aimed at treating podocyte injury-related renal diseases such as diabetic nephropathy, focal segmental glomerulosclerosis, and minimal change diseases. This development is significant as there are currently no targeted therapies available for podocyte protection, and the SK-09 Tablet could provide a more precise and effective treatment option, potentially alleviating the burden on patients and the healthcare system.
Consun Pharmaceutical Group Ltd. has announced the appointment of Mr. Young Yuk Chuen David as an executive director and Mr. Duan Weiwu as an independent non-executive director, effective from April 8, 2025. Mr. Young will focus on international investment projects and overseas business development, while Mr. Duan will contribute his extensive legal expertise to the audit and nomination committees. These appointments are expected to enhance the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations positively.
Consun Pharmaceutical Group Ltd. has announced the composition of its Board of Directors, which includes a mix of executive, non-executive, and independent non-executive directors. The Board has also established four committees: Audit, Remuneration, Nomination, and Environmental, Social and Governance, with designated chairpersons and members. This announcement reflects the company’s commitment to structured governance and oversight, potentially impacting its strategic direction and stakeholder confidence.
Consun Pharmaceutical Group Ltd. has appointed Professor Jonathan Barratt as a scientific advisor, enhancing its expertise in renal medicine. Professor Barratt’s extensive experience in nephrology and his leadership in international research networks are expected to significantly contribute to the company’s long-term growth and development in the pharmaceutical sector.
Consun Pharmaceutical Group Ltd. reported a strong financial performance for the year ended December 31, 2024, with a 14.6% increase in revenue to RMB2,967,235,000 and a 16.1% rise in profit attributable to equity shareholders, amounting to RMB910,458,000. The company also announced a proposed final dividend of HKD0.3 per share, reflecting its robust earnings growth and commitment to shareholder returns.
Consun Pharmaceutical Group Ltd. has announced a final ordinary dividend of HKD 0.3 per share for the financial year ending December 31, 2024. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders, with the dividend payment scheduled for June 20, 2025.
Consun Pharmaceutical Group Ltd. has announced the successful dosing of the first cohort in a Phase 1 clinical trial for their SK-08 Tablet, a Category 1 innovative drug targeting chronic kidney disease (CKD). The SK-08 Tablet, developed with a unique mechanism of action, aims to address the global health challenge posed by CKD by improving kidney function and reducing proteinuria. This development marks a significant milestone for the company, potentially filling a gap in CKD treatment options and reinforcing its commitment to innovative therapeutics.
Consun Pharmaceutical Group Ltd. has announced a board meeting scheduled for March 26, 2025, to discuss several key financial and operational matters. The agenda includes the approval of the audited consolidated financial statements for 2024, the draft announcement of these results, and considerations regarding a final dividend and the upcoming annual general meeting. This meeting is crucial for stakeholders as it will outline the company’s financial health and strategic decisions moving forward.
Consun Pharmaceutical Group Ltd. announced significant changes in its board composition and management, effective from February 24, 2025. Ms. Chen Yujun has resigned as an independent non-executive Director to take on the role of Chief Financial Officer, while Mr. Li Zhuoguang is appointed as an independent non-executive Director and the chairman of the Audit Committee. These changes reflect a strategic reallocation of responsibilities aimed at strengthening the company’s governance and financial oversight.